Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Apple
AAPL
|
+$953M |
| 2 |
NVIDIA
NVDA
|
+$784M |
| 3 |
Meta Platforms (Facebook)
META
|
+$753M |
| 4 |
Berkshire Hathaway Class A
BRK.A
|
+$316M |
| 5 |
Chipotle Mexican Grill
CMG
|
+$315M |
Top Sells
| 1 |
Amazon
AMZN
|
+$1.17B |
| 2 |
UnitedHealth
UNH
|
+$686M |
| 3 |
Tesla
TSLA
|
+$506M |
| 4 |
Abbott
ABT
|
+$388M |
| 5 |
Johnson & Johnson
JNJ
|
+$325M |
Sector Composition
| 1 | Technology | 20.29% |
| 2 | Healthcare | 16.94% |
| 3 | Consumer Discretionary | 12.83% |
| 4 | Consumer Staples | 9.16% |
| 5 | Industrials | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2501
The Honest Company
HNST
$445M
| $940K | ﹤0.01% |
559,666
-90,734
| -14% | -$152K |
|
2502
International General Insurance
IGIC
$1.02B
| $940K | ﹤0.01% |
105,134
+29,834
| +40% | +$267K |
|
2503
Ultralife
ULBI
$114M
| $937K | ﹤0.01% |
193,690
+17,000
| +10% | +$82.2K |
|
2504
Gold Resource Corp
GORO
$117M
| $935K | ﹤0.01% |
1,484,321
-29,703
| -2% | -$18.7K |
|
2505
iShares US Aerospace & Defense ETF
ITA
$9.25B
| $933K | ﹤0.01% |
+8,000
| New | +$933K |
|
2506
Eagle Bancorp Montana
EBMT
$138M
| $932K | ﹤0.01% |
70,410
-300
| -0.4% | -$3.97K |
|
2507
LGL Group
LGL
$34M
| $932K | ﹤0.01% |
195,834
-4,400
| -2% | -$20.9K |
|
2508
Thor Industries
THO
$5.5B
| $932K | ﹤0.01% |
9,000
-138,700
| -94% | -$14.4M |
|
2509
Fidelity Nasdaq Composite Index ETF
ONEQ
$8.82B
| $930K | ﹤0.01% |
+17,200
| New | +$930K |
|
2510
Simulations Plus
SLP
$311M
| $927K | ﹤0.01% |
21,400
-2,200
| -9% | -$95.3K |
|
2511
WisdomTree Emerging Markets SmallCap Dividend Fund
DGS
$1.69B
| $926K | ﹤0.01% |
19,900
-6,303
| -24% | -$293K |
|
2512
JPMorgan BetaBuilders Developed Asia Pacific-ex Japan ETF
BBAX
$5.53B
| $925K | ﹤0.01% |
19,345
+2,345
| +14% | +$112K |
|
2513
Viking Therapeutics
VKTX
$2.6B
| $924K | ﹤0.01% |
57,000
-704,200
| -93% | -$11.4M |
|
|
MITT
2514
AG Mortgage Investment Trust
MITT
$246M
| $922K | ﹤0.01% |
150,600
+21,700
| +17% | +$133K |
|
2515
Passage Bio
PASG
$22.3M
| $922K | ﹤0.01% |
48,955
+710
| +1% | +$13.4K |
|
2516
United Bankshares
UBSI
$5.26B
| $921K | ﹤0.01% |
+31,033
| New | +$921K |
|
2517
Verrica Pharmaceuticals
VRCA
$41.7M
| $919K | ﹤0.01% |
15,930
+10,280
| +182% | +$593K |
|
|
CTV
2518
DELISTED
Innovid Corp.
CTV
| $914K | ﹤0.01% |
+838,512
| New | +$914K |
|
2519
Mammoth Energy Services
TUSK
$111M
| $913K | ﹤0.01% |
188,972
-61,500
| -25% | -$297K |
|
2520
InnovAge Holding
INNV
$675M
| $912K | ﹤0.01% |
121,600
-800
| -0.7% | -$6K |
|
2521
iShares Exponential Technologies ETF
XT
$3.62B
| $912K | ﹤0.01% |
+16,400
| New | +$912K |
|
2522
NextDecade
NEXT
$1.71B
| $911K | ﹤0.01% |
+111,000
| New | +$911K |
|
2523
Oportun Financial
OPRT
$299M
| $911K | ﹤0.01% |
152,669
-39,640
| -21% | -$237K |
|
2524
IRIDEX
IRIX
$21.9M
| $910K | ﹤0.01% |
419,160
-3,900
| -0.9% | -$8.47K |
|
|
2525
Johnson & Johnson
JNJ
$427B
| $910K | ﹤0.01% |
5,500
-1,963,442
| -100% | -$325M |
|